Today: 13 May 2026
HawkEye 360 Stock Jumps 30% After $416 Million IPO as Defense-Space Demand Builds

HawkEye 360 Stock Jumps 30% After $416 Million IPO as Defense-Space Demand Builds

NEW YORK, May 8, 2026, 09:06 EDT

Shares of HawkEye 360 soared 30% as the satellite intelligence firm opened on the New York Stock Exchange Thursday, landing a valuation near $3.15 billion following its $416 million initial public offering. Edward Best, a partner with Willkie Farr & Gallagher, pointed to the IPO pricing as evidence of “strong market appetite for defense-related IPOs.” Investing.com

This deal stands out, offering public-market investors a seldom-seen chance to invest directly in signals intelligence—the tracking of radio and other electronic emissions to spot activity that conventional imagery can miss. CEO John Serafini, after ringing the opening bell, talked on Schwab Network about how the company leverages satellites for defense and military uses.

The IPO window is seeing action from space and defense players, not just the usual consumer or software names. HawkEye 360, which has significant defense ties, is now joining the public markets, according to Payload. Investors are also eyeing a potential SpaceX debut before year-end.

Hawkeye 360, out of Herndon, Virginia, priced its IPO at $26 a share, selling all 16 million on offer—the high end of its stated range. The deal, subject to standard closing conditions, was set to wrap up Friday. Goldman Sachs and Morgan Stanley took lead bookrunner roles, with RBC Capital Markets, Jefferies, and BofA Securities joining the syndicate.

HawkEye 360 runs a constellation of over 30 satellites, tracking radio-frequency activity tied to ships, radar, and GPS jamming. The Wall Street Journal noted that for 2025, the bulk of the company’s revenue came from the U.S. government—its top customer being the National Reconnaissance Office.

Sales hit roughly $118 million for 2025, a jump from last year’s $68 million, with net income at $2.7 million, according to Barron’s. The backlog closed out the year near $303 million. That’s something for investors to watch, though it doesn’t lock in future revenue.

HawkEye 360 plans to direct the IPO funds toward debt reduction, a deferred payment owed from its December purchase of Innovative Signal Analysis, and general working capital along with broader corporate purposes, according to Via Satellite. The ISA deal brought in extra signal-processing and classified intelligence tech—capabilities that align well with HawkEye 360’s focus on defense and intelligence agency contracts.

Competition stretches beyond a single IPO. Rocket Lab, for example, is already a public play on launch and spacecraft systems. York Space Systems, Firefly Aerospace, and Voyager Technologies have run their own listings, too—testing investor appetite for space. HawkEye, by contrast, is selling a tighter focus: electromagnetic spectrum data rather than rockets.

Still, there are serious risks here. HawkEye’s prospectus points out the market remains fairly young, its backlog isn’t guaranteed to convert to revenue, and many contracts let customers walk away. At the end of 2025, roughly 96% of backlog value came from just 10 customers. The company also warned that government budget changes, contract cancellations, or delays could quickly affect its performance.

The debut trade looked solid. The real challenge for HawkEye 360 begins post-IPO—turning defense contracts, interest from allied governments, and its constellation of satellites into consistent public-market earnings, all while hanging on to that opening-day valuation pop.

Stock Market Today

  • Analysts Cut 2026 Forecasts for Keel Infrastructure Despite Rising Share Price
    May 13, 2026, 9:41 AM EDT. Six analysts have downgraded their 2026 revenue and earnings forecasts for Keel Infrastructure Corp. (NASDAQ:KEEL), projecting a 43% drop in revenue to US$124 million and a 49% increase in losses per share to US$0.25. Previously, estimates showed US$146 million in revenue and slightly lower losses. Despite weaker guidance, the share price has risen 15% over the past week to US$4.07, and the consensus price target increased 5.2% to US$5.03. Industry comparisons reveal Keel is expected to grow more slowly than peers, with revenue shrinking versus a 17% annual growth forecast in the sector. Analysts' revised outlooks and warnings about a short cash runway suggest investor caution may be warranted.

Latest articles

Coherent Corp Stock: BofA’s $400 Call Puts AI Optics Back in Play

Coherent Corp Stock: BofA’s $400 Call Puts AI Optics Back in Play

13 May 2026
BofA raised its Coherent Corp. price target to $400, citing demand for high-speed optical transceivers used in AI data centers, but kept a Neutral rating. Coherent reported fiscal Q3 revenue up 21% to $1.81 billion, with Datacenter & Communications revenue jumping 41%. The stock traded near $374. China trade talks and export-control risks remain concerns for the sector.
WeRide Stock Slides Despite Record Q1 Revenue as Robotaxi Losses Loom

WeRide Stock Slides Despite Record Q1 Revenue as Robotaxi Losses Loom

13 May 2026
WeRide posted record Q1 revenue of RMB114.1 million, up 57.6% year-on-year, but its U.S.-listed shares fell 7.1% in premarket trading as losses stayed high. The company’s global robotaxi fleet reached about 1,300 vehicles by April 30. Net loss widened to RMB389.1 million, while R&D spending rose 11.5% to RMB363.3 million.
SoftBank Group Profit Surges on OpenAI Stake as $64 Billion Bet Faces Cash Test

SoftBank Group Profit Surges on OpenAI Stake as $64 Billion Bet Faces Cash Test

13 May 2026
SoftBank reported January-March net profit more than tripled to ¥1.83 trillion, driven by gains from its OpenAI stake. Full-year net income rose to ¥5.002 trillion, the highest ever by a Japanese company. SoftBank’s OpenAI investment reached $34.6 billion as of March 31, set to increase to $64.6 billion after planned 2026 tranches. The company drew $20 billion from a $40 billion bridge loan to fund additional OpenAI investments.

Popular

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

13 May 2026
SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
Fluence Energy Stock Jumps Again: Why Wall Street Is Watching Its $5.6 Billion Backlog
Previous Story

Fluence Energy Stock Jumps Again: Why Wall Street Is Watching Its $5.6 Billion Backlog

Wall Street’s New AI Chip Bet Just Took In $1 Billion In One Day
Next Story

Wall Street’s New AI Chip Bet Just Took In $1 Billion In One Day

Go toTop